RT Journal Article
SR Electronic
T1 A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22269742
DO 10.1101/2022.02.17.22269742
A1 Anscombe, Catherine
A1 Lissauer, Samantha
A1 Thole, Herbert
A1 Rylance, Jamie
A1 Dula, Dingase
A1 Menyere, Mavis
A1 Kutambe, Belson
A1 van der Veer, Charlotte
A1 Phiri, Tamara
A1 Banda, Ndaziona P.
A1 Mndolo, Kwazizira S.
A1 Mponda, Kelvin
A1 Phiri, Chimota
A1 Mallewa, Jane
A1 Nyirenda, Mulinda
A1 Katha, Grace
A1 Mwandumba, Henry
A1 Gordon, Stephen B.
A1 Jambo, Kondwani C.
A1 Cornick, Jennifer
A1 Feasey, Nicholas
A1 Barnes, Kayla G.
A1 Morton, Ben
A1 Ashton, Philip M.
A1 Blantyre COVID-19 Consortium
YR 2022
UL http://medrxiv.org/content/early/2022/07/11/2022.02.17.22269742.abstract
AB Background Compared to the abundance of clinical and genomic information available on patients hospitalised with COVID-19 disease from high-income countries, there is a paucity of data from low-income countries. Our aim was to explore the relationship between viral lineage and patient outcome.Methods We enrolled a prospective observational cohort of adult patients hospitalised with PCR-confirmed COVID-19 disease between July 2020 and March 2022 from Blantyre, Malawi, covering four waves of SARS-CoV-2 infections. Clinical and diagnostic data were collected using an adapted ISARIC clinical characterization protocol for COVID-19. SARS-CoV-2 isolates were sequenced using the MinION™ in Blantyre.Results We enrolled 314 patients, good quality sequencing data was available for 55 patients. The sequencing data showed that 8 of 11 participants recruited in wave one had B.1 infections, 6/6 in wave two had Beta, 25/26 in wave three had Delta and 11/12 in wave four had Omicron. Patients infected during the Delta and Omicron waves reported fewer underlying chronic conditions and a shorter time to presentation. Significantly fewer patients required oxygen (22.7% [17/75] vs. 58.6% [140/239], p<0.001) and steroids (38.7% [29/75] vs. 70.3% [167/239], p<0.001) in the Omicron wave compared with the other waves. Multivariable logistic-regression demonstrated a trend toward increased mortality in the Delta wave (OR 4.99 [95% CI 1.0-25.0 p=0.05) compared to the first wave of infection.Conclusions Our data show that each wave of patients hospitalised with SARS-CoV-2 was infected with a distinct viral variant. The clinical data suggests that patients with severe COVID-19 disease were more likely to die during the Delta wave.Summary We used genome sequencing to identify the variants of SARS-CoV-2 causing disease in Malawi, and found that each of the four waves was caused by a distinct variant. Clinical investigation suggested that the Delta wave had the highest mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [220757/Z/20/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were approved by the Malawi National Health Science Research Committee (NHSRC, 20/02/2518 and 19/08/2246) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTM REC, 20/026 and 19/017).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genome sequences are available in GISAID. Accessions are available in Supplementary Table 2.